Ana Kerguelen - Concepedia

Author

Ana Kerguelen

Also Known As

A Kerguelen, A Payer, A. Kerguelen, Ana Esther Kerguelén, Ana Kerguelen, Francisca Ferrer-Marín, K. Humala, Melania Moreno

Publications

765

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario La Paz Hospital Clínico Universitario de Valencia Hospital Del Mar Hospital Universitario Ramón y Cajal Hospital General Universitario Morales Meseguer

About

Ana Kerguelen is an author at Hospital Universitario La Paz specializing in hematology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	324
2	Health Sciences	3	3	150
3	Public Health	2	2	68
4	Epidemiology	2	2	68
5	Cell Biology	1	1	53

Ana Kerguelen

Publications

524

Citations

H-Index

Page 1

	Year	Citations
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation Alberto Álvarez‐Larrán, Arturo Pereira, Paola Guglielmelli, Haematologica	2016	145
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera Alberto Álvarez‐Larrán, Ana Kerguelen, Juan Carlos Hernández‐Boluda, British Journal of Haematology PharmacotherapyLogistic AnalysisMyeloid NeoplasiaHematological MalignancyDrug Resistance	2015	77
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea Alberto Álvarez‐Larrán, Manuel Pérez‐Encinas, Francisca Ferrer‐Marín, Haematologica ThrombopoiesisThrombosisPolycythemia VeraUrologyVenous Thrombosis	2016	72
The occurrence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product Raúl Córdoba, R Arrieta, Ana Kerguelen, Bone Marrow Transplantation Regenerative MedicineAdverse EventsBone Marrow FailureMarrow TransplantationGranulocyte	2007	53
<i>JAK2</i>V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events Alberto Álvarez‐Larrán, Beatríz Bellosillo, Arturo Pereira, American Journal of Hematology Essential ThrombocythemiaMyelofibrotic TransformationImmunologyPathologyMyeloid Neoplasia	2014	48
Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis Juan Carlos Hernández‐Boluda, Juan Gonzalo Correa, Regina García‐Delgado, European Journal Of Haematology	2016	35
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk Francisca Ferrer‐Marín, Ana B. Arroyo, Beatríz Bellosillo, Leukemia Hematological MalignancyMir-146a Rs2431697 IdentifiesMedicineHematologyImmunology	2020	22
Long-term results of prednisone treatment for the anemia of myelofibrosis Juan Carlos Hernández‐Boluda, Alejandra Martínez‐Trillos, Valentín García‐Gutiérrez, Leukemia & lymphoma/Leukemia and lymphoma InflammationThrombosisHematological MalignancyBone Marrow FailureSingle-agent Prednisone	2015	20
Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution Rodrigo Martino, Ana Kerguelen, David Valcárcel, Bone Marrow Transplantation Infection-related MortalitySusceptible HostPathogenesisHematologyGenetic Epidemiology	2010	20
Risk factors for non‐melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera Montse Gómez, Vicent Guillem, Arturo Pereira, European Journal Of Haematology	2015	20

Page 1